$RHHBY News
Last published 1d ago
- 1d agoRHHBYRoche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer’s disease portfolio at CTAD 2026GlobeNewswireUpdated Phase Ib/IIa Brainshuttle™ AD study data for trontinemab demonstrating rapid amyloid removal dynamics and changes in key biomarkers Phase III PrevenTRON study design specifics for trontinemab in preclinical
- 1d agoRHHBYGenentech and Roche Present New Data Across Pharmaceuticals and Diagnostics From Its Growing Alzheimer’s Disease Portfolio at CTAD 2026Business WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that it will present new data across its pharmaceuticals and diagnostics portfolios at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Congress, taking place in Boston from November 16-19, 2026. Across 16 accepted abstracts, including two scientific symposia and ...
- 1w agoPNGAFRHHBYNVOVKTX+1Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 BillionGlobeNewswireNEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Peptide-based treatments are attracting growing attention from major pharmaceutical companies as researchers push into new ways to treat diabetes, obesity, cancer, metabolic
- 2w agoRHHBYRoche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesotheliomaGlobeNewswireThe VENTANA BAP1 (SP527) test helps confidently distinguish malignant mesothelioma from lung, breast and stomach cancers, as well as benign tissue growth in the chest or abdomen.Most patients are diagnosed with
- 2w agoRHHBYRoche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratoriesGlobeNewswireThe cobas smart e immunoanalyser – the newest addition to Roche’s industry-leading cobas immunoassay systems portfolio – is engineered to deliver central-lab performance in a footprint under one square metre. With a
- 2w agoLLYNVOAZNRHHBYBillions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two DecadesGlobeNewswireDENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Eli Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO), AstraZeneca (NYSE:AZN), and Roche (OTCQX:RHHBY) are among the biopharma companies committing billions of
- 2w agoRHHBYGenentech’s Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung CancerBusiness WireDivarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the Phase III
- 2w agoRHHBYRoche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancerGlobeNewswireDivarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the phase III Krascendo
- 2w agoRHHBYRoche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)GlobeNewswireSefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient
- 2w agoRHHBYGenentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)Business Wire- Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient
- 2w agoRHHBY[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]GlobeNewswireAd hoc announcement pursuant to Art. 53 LRBasel, 22 October 2026 Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6%
- 3w agoRHHBYRoche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026GlobeNewswireFenebrutinib FENtrepid and FENhance 1 & 2 late-breaking data demonstrate a therapeutic effect on chronic active lesions, addressing a primary driver of long-term disability progression in multiple sclerosis
- 3w agoRHHBYGenentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026Business WireFenebrutinib FENtrepid and FENhance 1 & 2 late-breaking data demonstrate a therapeutic effect on chronic active lesions, addressing a primary driver of long-term disability progression in multiple sclerosis
- 3w agoRHHBYRoche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolioGlobeNewswirePhase III Krascendo 1 results demonstrated divarasib’s superiority over current standard of care, first-generation KRAS G12C inhibitors in previously treated advanced G12C-mutated non-small cell lung
- 3w agoRHHBYGenentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage PortfolioBusiness WirePhase III Krascendo 1 results demonstrated divarasib’s superiority over current standard of care, first-generation KRAS G12C inhibitors, in previously treated advanced G12C-mutated non-small cell lung
- 3w agoRHHBYFDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)GlobeNewswireFDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favourable safety profile,
- 3w agoRHHBYFDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)Business WireFDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favorable safety profile,
- 1mo agoRHHBYGenentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision LossBusiness WireIn the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks UME is the leading cause of moderate and severe
- 1mo agoRHHBYRoche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision lossGlobeNewswireIn the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks1,2UME is the leading cause of moderate and severe vision
- 1mo agoRHHBYFDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancerGlobeNewswireFDA approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by
- 1mo agoRHHBYFDA Approves Genentech’s Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon CancerBusiness WireFDA approval is based on results from the landmark Phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by
- 1mo agoRHHBYGenentech and Breastcancer.org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment EndsBusiness WireMore than 225,000 women in the U.S. are expected to be diagnosed with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer this year,1 the most common form of the
- 1mo agoRHHBYGenentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal ConditionsBusiness WireNew real-world results for Vabysmo in wet AMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals Advanced AI-enabled analysis of
- 1mo agoRHHBYGenentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of MedicineBusiness WireGiredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy plus everolimus By targeting
- 1mo agoRHHBYGenentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple SclerosisBusiness WireFenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in delaying disability Fenebrutinib became the first investigational
- 1mo agoRHHBYGenentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, OregonBusiness WireExpansion adds 211,000 square feet to the site, supported by approximately 200 construction jobs Investment creates approximately 250 high-wage jobs pairing manufacturing expertise with digital skills in AI,
- 1mo agoRHHBYPositive Interim Data Shows Genentech’s Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN)Business WireIn the Phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential Sefaxersen
- 1mo agoRHHBYGenentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or ObesityBusiness Wire● At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycemic control ● In patients with poor baseline glycemic control
- 1mo agoRHHBY[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesityGlobeNewswireAt the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycemic controlIn patients with poor baseline glycemic control (HbA1c
- 1mo agoRHHBYEuropean Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)GlobeNewswireBy continuously delivering medicine into the eye through the Contivue refillable implant, Susvimo is the first and only continuous delivery treatment that offers an alternative to standard-of-care eye injections for
- 1mo agoRHHBYCHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosisGlobeNewswireOcrevus addresses a critical need in paediatric neurology as the first high- efficacy anti-CD20 treatment option for people with MS as young as 10 years old In the Phase III OPERETTA 2 study, Ocrevus demonstrated
- 1mo agoRHHBYRoche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseasesGlobeNewswireThe center will be a hub for Roche and Genentech, bringing together expertise in Cardiovascular, Renal and Metabolism, as well as for data science and AI specialists to drive innovation in drug discovery and
- 1mo agoRHHBYGenentech and Roche Announce Grand Opening of Boston R&D Innovation CenterBusiness WireRoche Genentech Innovation Center Boston strengthens its research presence in Boston, reflecting a long-term commitment to one of the world’s leading life sciences hubs Research focuses on cardiovascular, renal and
- 1mo agoRHHBYRoche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO studyGlobeNewswirePhase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular
- 1mo agoRHHBYGenentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO StudyBusiness WirePhase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular
- 2mo agoRHHBYRoche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancerGlobeNewswireTambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving
- 2mo agoRHHBYU.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved TreatmentsBusiness WireIf approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease) Filing acceptance is based on the Phase III METEOROID study
- 2mo agoRHHBYU.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatmentsGlobeNewswireIf approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease)Filing acceptance is based on the Phase III METEOROID study showing
- 2mo agoQNTMSNYRHHBYBIIB+1A Micro-Cap Biotech Just Cleared a Milestone Most Never ReachGlobeNewswireAUSTIN, Texas, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis ("MS") drugs on the market today can slow the disease down, but none of them stop it, and none of them give
- 2mo agoRHHBYTreeline Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate TLN-121 in Combination with CD20xCD3 T-Cell-Engaging Bispecific AntibodiesBusiness WireAgreement will evaluate Treeline's BCL6 degrader TLN-121 with Roche’s glofitamab-gxbm (COLUMVI®) and mosunetuzumab-axgb (LUNSUMIO®) for the treatment of B-cell lymphomas Preclinical TLN-121 data show enhanced
- 2mo agoRHHBYRoche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD)GlobeNewswireThe SALWEEN study showed significant improvements in vision and retinal health1 More than 60% of Asian patients with polypoidal choroidal vasculopathy (PCV), an aggressive subtype of nAMD, treated with Vabysmo showed no
- 2mo agoRHHBYRoche’s US subsidiary Genentech announces manufacturing expansion in the United StatesGlobeNewswireNew facility in Hillsboro, Oregon for the assembly of injectable medicines and delivery devices will further advance end-to-end U.S. drug manufacturing capabilities.Approximately $750 million investment will double the
- 2mo agoRHHBYGenentech Announces Manufacturing Expansion in Hillsboro, OregonBusiness WireNew device fill-finish facility will advance Genentech’s efforts to build end-to-end U.S. drug manufacturing capabilities, supporting a more secure and resilient domestic medicine supply chain Approximately $750
- 2mo agoRHHBYGenentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing FacilityBusiness WireGenentech celebrates the completion of the $2 billion facility’s structural framework of its state-of-the-art biomanufacturing facility, which is expected to support 1,500+ construction jobs and 500+ high-wage
- 3mo agoRHHBYCHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)GlobeNewswireSusvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye injections for nAMDPositive recommendation is based on data from the LADDER, Archway and Portal studies
- 3mo agoRHHBY[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss francGlobeNewswireGroup sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2, in the first six months, driven by high demand for innovative medicines and diagnostics.Pharmaceuticals Division sales
- 3mo agoRHHBYFDA Grants Priority Review to Genentech’s Gazyva for Adults With Primary Membranous NephropathyBusiness WirePriority review decision is based on Phase III MAJESTY results, where Gazyva achieved significantly higher complete remission rates at two years compared to tacrolimus If approved, Gazyva will be the first
- 3mo agoRHHBYFDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathyGlobeNewswirePriority Review decision is based on phase III MAJESTY results, where Gazyva/Gazyvaro achieved significantly higher complete remission rates at two years compared to tacrolimus1 If approved, Gazyva/Gazyvaro will be the
- 4mo agoRHHBYRoche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitisGlobeNewswireThe new test enables clinicians to reliably diagnose HDV and monitor patients’ treatment response.Hepatitis D affects nearly 12 million of people globally and is considered the most aggressive form of viral hepatitis,
- 4mo agoRHHBYRoche receives CE Mark for blood test to identify tuberculosis infectionGlobeNewswireThe Elecsys IGRA TB test expands global access to tuberculosis infection testing, advancing progress toward the World Health Organization's elimination targets.Performed on Roche’s industry-leading and widely